Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Retained Earnings (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Retained Earnings for 8 consecutive years, with $56000.0 as the latest value for Q1 2026.

  • Quarterly Retained Earnings fell 75.22% to $56000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $56000.0 through Feb 2026, down 75.22% year-over-year, with the annual reading at -$1.0 billion for FY2025, 668917.33% down from the prior year.
  • Retained Earnings for Q1 2026 was $56000.0 at Nurix Therapeutics, up from -$1.0 billion in the prior quarter.
  • The five-year high for Retained Earnings was $226000.0 in Q1 2025, with the low at -$1.0 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$268.0 million, with a median of -$4.3 million recorded in 2022.
  • Peak annual rise in Retained Earnings hit 164.57% in 2025, while the deepest fall reached 668917.33% in 2025.
  • Over 5 years, Retained Earnings stood at -$4.3 million in 2022, then skyrocketed by 84.83% to -$655000.0 in 2023, then surged by 122.9% to $150000.0 in 2024, then crashed by 668917.33% to -$1.0 billion in 2025, then skyrocketed by 100.01% to $56000.0 in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $56000.0, -$1.0 billion, and $119000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.